ELDN Eledon Pharmaceuticals
- 2.505
- +0.165+7.05%
- 2.530
- +0.025+1.00%
Eledon Pharmaceuticals News
Eledon Pharmaceuticals | 10-Q: Quarterly report
HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $16 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Eledon Pharma with a Buy and maintains $16 price target.
Eledon Pharmaceuticals' Tegoprubart Shows Promising Trial Results and Fuels Buy Rating
Eledon Pharma Q1 2024 GAAP EPS $(0.34) Beats $(0.39) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 54.67 percent increase over losses of $(0.75
Eledon Pharmaceuticals Completed Oversubscribed $50 M Private Placement >ELDN
Eledon Pharmaceuticals Completed Oversubscribed $50 M Private Placement >ELDN
Eledon Pharmaceuticals 1Q Loss/Shr 34c >ELDN
Eledon Pharmaceuticals 1Q Loss/Shr 34c >ELDN
Press Release: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Ch
Eledon Pharmaceuticals to Present Updated Data From Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) ta
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart
Eledon Pharmaceuticals' Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price Target
Eledon Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Eledon Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Eledon Pharma (ELDN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $16.00.
HC Wainwright & Co. : The Eledon Pharma (ELDN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $16.00.
HC Wainwright & Co. Maintains Buy on Eledon Pharma, Raises Price Target to $16
HC Wainwright & Co. analyst Vernon Bernardino maintains Eledon Pharma with a Buy and raises the price target from $13 to $16.
Eledon Pharmaceuticals Shares Are Trading Lower After the Company Announced an $50 Million Oversubscribed Private Placement. The Company Announced Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection.
Eledon Pharmaceuticals Shares Are Trading Lower After the Company Announced an $50 Million Oversubscribed Private Placement. The Company Announced Clinical Progress With Tegoprubart in the Prevention
Eledon Pharmaceuticals To Use Net Proceeds to Fund Pre-Comml Activities for Products, General Corporate Purposes >ELDN
Eledon Pharmaceuticals To Use Net Proceeds to Fund Pre-Comml Activities for Products, General Corporate Purposes >ELDN
Eledon Pharmaceuticals to Sell 13.1M Shares at $2.37 a Share>ELDN
Eledon Pharmaceuticals to Sell 13.1M Shares at $2.37 a Share>ELDN
Eledon Pharmaceuticals: Entered Into Securities Purchase Agreement With Certain Institutional, Accredited Healthcare Investors >ELDN
Eledon Pharmaceuticals: Entered Into Securities Purchase Agreement With Certain Institutional, Accredited Healthcare Investors >ELDN
Eledon Announces Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has entered into a securities purchase agreement with certain institut
Analysis
Price Target
No Data
